Key Points
- Arcus Biosciences CAO Alexander Azoy sold 2,827 shares at an average price of $30, generating $84,810. The Rule 10b5-1 transaction reduced his holdings by 6.67% to 39,581 shares.
- Arcus reported a quarterly loss of $0.72 per share, beating estimates for a $0.89 loss, while revenue of $41 million exceeded expectations but declined 74.4% year over year.
- Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $37.80, compared with the stock’s reported opening price of $30.20.
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,187,430. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alexander Azoy also recently made the following trade(s):
- On Monday, June 1st, Alexander Azoy sold 2,562 shares of Arcus Biosciences stock. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74.
Arcus Biosciences Trading Down 0.5%
Shares of RCUS stock opened at $30.20 on Tuesday. Arcus Biosciences, Inc. has a 52-week low of $10.07 and a 52-week high of $31.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. The firm has a market capitalization of $3.85 billion, a PE ratio of -7.74 and a beta of 0.80. The stock has a fifty day simple moving average of $28.62 and a two-hundred day simple moving average of $24.84.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The business had revenue of $41.00 million for the quarter, compared to the consensus estimate of $21.98 million. The firm's revenue was down 74.4% compared to the same quarter last year. On average, analysts predict that Arcus Biosciences, Inc. will post -3.53 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company's stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Arcus Biosciences during the fourth quarter valued at $39,000. KBC Group NV bought a new position in Arcus Biosciences during the first quarter valued at $50,000. GAMMA Investing LLC lifted its position in Arcus Biosciences by 10.0% during the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company's stock valued at $122,000 after purchasing an additional 359 shares during the last quarter. Finally, Nykredit A S bought a new position in Arcus Biosciences during the second quarter valued at $134,000. 92.89% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. Lifesci Capital started coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They set an "outperform" rating and a $46.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Arcus Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Morgan Stanley set a $23.00 price target on shares of Arcus Biosciences in a research note on Monday, August 10th. Finally, Wells Fargo & Company raised their price objective on Arcus Biosciences from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $37.80.
Get Our Latest Research Report on RCUS
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.
The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
